Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05011513 |
|
Recruitment Status :
Terminated
(Enrollment ceased due to a very low rate of hospitalization or death observed in the standard-risk patient population)
First Posted : August 18, 2021
Last Update Posted : December 12, 2022
|
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | July 25, 2022 |
| Actual Study Completion Date : | July 25, 2022 |